Endocrine Abstracts

Medical therapy of patients with acromegaly is an important addition to surgical treatment or an alternative to it when it is impossible to use the latter. Long-acting synthetic analogues of somatostatin (octreotide and lanreotide) act on the same subtypes of somatostatin receptors, but the drugs have been shown to differ in efficacy and tolerability.

Objective: to achieve complete clinical and laboratory remission in patients with acromegaly, which did not reach it when using prolonged octreotide.

Materials and methods: 12 patients with acromegaly who did not have clinical and laboratory remission during treatment with octreotide Depo (Long), while only 3 patients had incomplete clinical and laboratory remission. Of these, surgical treatment was performed in 9 patients. The mean age of the patient is 52.3 years. The patients were switched from octreotide Depo (Long) 30 mg (5 people) and octreotide Depo (Long) 40 mg (7 people) to Somatulin Autogel 120 mg somatulin. The interval between injections was 28 days. Controlled the level of growth hormone (GH) and insulin-like growth factor 1 (IGF-1)

Results: During 6 months of therapy, 10 patients showed a significant decrease in growth hormone (P=0.024) and IGF-1 (P=0.041), while the level of IGF-1 was completely normalized in 3 people, and growth hormone - in 3 people. After 12 months, complete clinical and laboratory remission was observed in 4 patients, partial - in 4 patients. Thus, after a year of observation, 8 out of 12 patients achieved remission.

Conclusions: Patients who have not achieved remission on long-acting octreotide should be switched to long-acting lanreotide (Somatulin Autogel)